Physician profile
Edward E Elliott
NPI 1518412105
$6,564.63
in general payments reported to CMS, 2019-2025
33 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,522 · 2022: $1,346 · 2023: $1,944 · 2024: $1,645 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,612.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $884.59 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $704.82 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $601.14 | 2021-2025 | |
| Amgen INC. | $420.30 | 2021-2024 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $272.39 | 2022-2024 | |
| Pfizer INC. | $266.37 | 2021-2024 | |
| Abbott Laboratories | $194.79 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.85 | 2021-2023 | Jardiance, Synjardy |
| Exact Sciences Corporation | $174.93 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $136.24 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $130.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $109.26 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $106.04 | 2023-2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $88.46 | 2024-2025 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $84.56 | 2021-2022 | |
| Insulet Corporation | $78.21 | 2022-2023 | Omnipod |
| Esperion Therapeutics, INC. | $73.64 | 2021 | |
| Shield Therapeutics INC | $50.53 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.12 | 2021-2022 | |
| Inspire Medical Systems, INC. | $42.21 | 2023 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $40.47 | 2022 | |
| Merck Sharp & Dohme LLC | $38.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.86 | 2021 | |
| Smith+Nephew, INC. | $32.81 | 2024 | Grafix |
| Mylan Specialty L.P. | $29.05 | 2022 | |
| Irhythm Technologies, INC. | $25.51 | 2022 | |
| Allergan, INC. | $19.07 | 2021 | |
| Dexcom, INC. | $18.85 | 2022 | |
| Eisai INC. | $17.13 | 2024 | |
| Axsome Therapeutics, INC. | $16.50 | 2023 | Auvelity |
| Currax Pharmaceuticals LLC | $15.90 | 2023 | Contrave |
| Idorsia Pharmaceuticals US INC | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.